Ho-Yen et al. [108] showed that the HGF/c-MET pathway is associated with breast cancer progression suggesting that there is a solid rationale for continuing to develop anti-c-MET drugs, particularly for patients without many options available like those with basal-like and triple-negative breast cancer. This evidence concerns the gene MET and triple-negative breast carcinoma.